Treatment of refractory Hodgkin's lymphoma patients with an iodine-131-labeled murine anti-CD30 monoclonal antibody

Journal of Clinical Oncology

Volumn 23, Issue 21, 2005, Pages 4669-4678

  Schnell, Roland ^a   Dietlein, Markus ^a   Staak, Jan Oliver ^a   Borchmann, Peter ^a   Schomaecker, Klaus ^a   Fischer, Thomas ^a   Eschner, Wolfgang ^a   Hansen, Hinrich ^a   Morschhauser, Franck ^a   Schicha, Harald ^a   Diehl, Volker ^a   Raubitschek, Andrew ^a   Engert, Andreas ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CARMUSTINE; CHLORMETHINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DACARBAZINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; GEMCITABINE; IDARUBICIN; IFOSFAMIDE; INTERLEUKIN 2; LOMUSTINE; MELPHALAN; MITOXANTRONE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY I 131; MONOCLONAL ANTIBODY KI 4; MONOCLONAL ANTIBODY KI 4 I 131; NAVELBINE; PREDNIMUSTINE; PREDNISOLONE; PREDNISONE; PROCARBAZINE; RITUXIMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINBLASTINE; VINCRISTINE; ANTIBODY CONJUGATE; CD30 ANTIGEN; RADIOACTIVE IODINE;

ADOLESCENT; ADULT; ANEMIA; ARTICLE; BLOOD TOXICITY; CANCER REGRESSION; CLINICAL ARTICLE; CONTROLLED STUDY; DOSIMETRY; DRUG MEGADOSE; DRUG TOLERABILITY; FATIGUE; FEMALE; GASTRITIS; HODGKIN DISEASE; HUMAN; ISOTOPE LABELING; LEUKOPENIA; LYMPH NODE PAIN; MALE; NAUSEA; NEUTROPENIA; PRIORITY JOURNAL; SKIN ULCER; THROMBOCYTOPENIA; TREATMENT RESPONSE; URTICARIA; WHOLE BODY SCINTISCANNING; ANIMAL; IMMUNOLOGY; IMMUNOTHERAPY; METHODOLOGY; MOUSE; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD30; HODGKIN DISEASE; HUMANS; IMMUNOCONJUGATES; IMMUNOTHERAPY; IODINE RADIOISOTOPES; MICE; TREATMENT OUTCOME;

EID: 23044516378     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.09.098     Document Type: Article

References (51)

1. Longo DL, Young RC, Wesley M, et al: Twenty years of MOPP therapy for Hodgkin's disease. J Clin Oncol 4:1295-1306, 1986
2. Bonadonna G, Santoro A, Bonfante V, et al: Cyclic delivery of MOPP and ABVD combinations in stage IV Hodgkin's disease: Rationale, background studies, and recent results. Cancer Treat Rep 66:881-887, 1982
3. Diehl V, Franklin J, Pfreundschuh M, et al: Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. N Engl J Med 348: 2386-2395, 2003
4. Devita VT Jr, Serpick AA, Carbone PP: Combination chemotherapy in the treatment of advanced Hodgkin's disease. Ann Intern Med 73:881-895, 1970
5. Kaplan HS: Hodgkin's disease: Unfolding concepts concerning its nature, management and prognosis. Cancer 45:2439-2474, 1980
6. Popat U, Hosing C, Saliba RM, et al: Prognostic factors for disease progression after high-dose chemotherapy and autologous hematopoietic stem cell transplantation for recurrent or refractory Hodgkin's lymphoma. Bone Marrow Transplant 33:1015-1023, 2004
7. Carella AM: Indications for autologous bone marrow transplantation in Hodgkin's disease. Leuk Lymphoma 7:21-22, 1992 (suppl)
8. Josting A, Rudolph C, Mapara M, et al: Cologne high-dose sequential chemotherapy in relapsed and refractory Hodgkin lymphoma: Results of a large multicenter study of the German Hodgkin Lymphoma Study Group (GHSG). Ann Oncol 16:116-123, 2005
9. Josting A, Reiser M, Rueffer U, et al: Treatment of primary progressive Hodgkin's and aggressive non-Hodgkin's lymphoma: Is there a chance for cure? J Clin Oncol 18:332-339, 2000
10. Gribben JG, Freedman A, Woo SD, et al: All advanced stage non-Hodgkin's lymphomas with a polymerase chain reaction amplifiable breakpoint of bcl-2 have residual cells containing the bcl-2 rearrangement at evaluation and after treatment. Blood 78:3275-3280, 1991
11. Kanzler H, Hansmann ML, Kapp U, et al: Molecular single cell analysis demonstrates the derivation of a peripheral blood-derived cell line (L1236) from the Hodgkin/Reed-Sternberg cells of a Hodgkin's lymphoma patient. Blood 87: 3429-3436, 1996
12. Agnarsson BA, Kadin ME: The immunophenotype of Reed-Sternberg cells: A study of 50 cases of Hodgkin's disease using fixed frozen tissues. Cancer 63:2083-2087, 1989
13. Stein H, Mason DY, Gerdes J, et al: The expression of the Hodgkin's disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: Evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells. Blood 66:848-858, 1985
14. Chiarle R, Podda A, Prolla G, et al: CD30 overexpression enhances negative selection in the thymus and mediates programmed cell death via a Bcl-2-sensitive pathway. J Immunol 163:194-205, 1999
15. Chiarle R, Podda A, Prolla G, et al: CD30 in normal and neoplastic cells. Clin Immunol 90: 157-164, 1999
16. Wiley SR, Goodwin RG, Smith CA: Reverse signaling via CD30 ligand. J Immunol 157: 3635-3639, 1996
17. Horie R, Watanabe T: CD30: Expression and function in health and disease. Semin Immunol 10:457-470, 1998
18. Higgins JP, Warnke RA: CD30 expression is common in mediastinal large B-cell lymphoma. Am J Clin Pathol 112:241-247, 1999
19. Leroy X, Augusto D, Leteurtre E, et al: CD30 and CD117 (c-kit) used in combination are useful for distinguishing embryonal carcinoma from seminoma. J Histochem Cytochem 50:283-285, 2002
20. Stein H, Foss HD, Durkop H, et al: CD30(+) anaplastic large cell lymphoma: A review of its histopathologic, genetic, and clinical features. Blood 96:3681-3695, 2000
21. Ralfkiaer E, Bosq J, Gatter KC, et al: Expression of a Hodgkin and Reed-Sternberg cell associated antigen (Ki-1) in cutaneous lymphoid infiltrates. Arch Dermatol Res 279:285-292, 1987
22. Falini B, Bolognesi A, Flenghi L, et al: Response of refractory Hodgkin's disease to monoclonal anti-CD30 immunotoxin. Lancet 339: 1195-1196, 1992
23. Engert A, Diehl V, Schnell R, et al: A phase-I study of an anti-CD25 ricin A-chain immunotoxin (RFT5-SMPT-dgA) in patients with refractory Hodgkin's lymphoma. Blood 89:403-410, 1997
24. Schnell R, Vitetta E, Schindler J, et al: Treatment of refractory Hodgkin's lymphoma patients with an anti-CD25 ricin A-chain immunotoxin. Leukemia 14:129-135, 2000
25. Schnell R, Staak O, Borchmann P, et al: A Phase I study with an anti-CD30 ricin A-chain immunotoxin (Ki-4.dgA) in patients with refractory CD30+ Hodgkin's and non-Hodgkin's lymphoma. Clin Cancer Res 8:1779-1786, 2002
26. Schnell R, Borchmann P, Staak JO, et al: Clinical evaluation of ricin A-chain immunotoxins in patients with Hodgkin's lymphoma. Ann Oncol 14:729-736, 2003
27. Hartmann F, Renner C, Jung W, et al: Treatment of refractory Hodgkin's disease with an anti-CD16/CD30 bispecific antibody. Blood 89:2042-2047, 1997
28. Hartmann F, Renner C, Jung W, et al: Anti-CD16/CD30 bispecific antibody treatment for Hodgkin's disease: Role of infusion schedule and costimulation with cytokines. Clin Cancer Res 7:1873-1881, 2001
29. Borchmann P, Staak JO, Fuss I, et al: Phase I trial of a novel anti CD64xCD30 bispecific molecule in patients with refractory Hodgkin's disease. Blood 96:730a, 2000
30. Wahl AF, Klussman K, Thompson JD, et al: The anti-CD30 monoclonal antibody SGN-30 promotes growth arrest and DNA fragmentation in vitro and affects antitumor activity in models of Hodgkin's disease. Cancer Res 62:3736-3742, 2002
31. Barlett NL, Carabasi MA, Espina B, et al: Phase I study of SGN-30, a chimeric monoclonal antibody (mAb), in patients with refractory or recurrent CD30-positive hematologic malignancies. Blood 100, 2002 (abstr 1403)
32. Borchmann P, Treml JF, Hansen H, et al: The human anti-CD30 antibody 5F11 shows in vitro and in vivo activity against malignant lymphoma. Blood 102:3737-3742, 2003
33. Bierman PJ, Vose JM, Leichner PK, et al: Yttrium 90-labeled antiferritin followed by high-dose chemotherapy and autologous bone marrow transplantation for poor-prognosis Hodgkin's disease. J Clin Oncol 11:698-703, 1993
34. Herpst JM, Klein JL, Leichner PK, et al: Survival of patients with resistant Hodgkin's disease after polyclonal yttrium 90-labeled antiferritin treatment. J Clin Oncol 13:2394-2400, 1995
35. Lenhard RE Jr, Order SE, Spunberg JJ, et al: Isotopic immunoglobulin: A new systemic therapy for advanced Hodgkin's disease. J Clin Oncol 3:1296-1300, 1985
36. Vriesendorp HM, Herpst JM, Germack MA, et al: Phase I-II studies of yttrium-labeled antiferritin treatment for end-stage Hodgkin's disease, including Radiation Therapy Oncology Group 87-01. J Clin Oncol 9:918-928, 1991
37. Vriesendorp HM, Quadri SM, Wyllie CT, et al: Fractionated radiolabeled antiferritin therapy for patients with recurrent Hodgkin's disease. Clin Cancer Res 5:3324s-3329s, 1999
38. Horn-Lohrens O, Tiemann M, Lange H, et al: Shedding of the soluble form of CD30 from the Hodgkin-analogous cell line L540 is strongly inhibited by a new CD30-specific antibody (Ki-4). Int J Cancer 60:539-544, 1995
39. Greenwood FC, Hunter WM, Glover JS: The preparation of I-131-labelled human growth hormone of high specific radioactivity. Biochem J 89:114-123, 1963
40. Scatchard G: The attraction of proteins for small molecules and ions. Ann NY Acad Sci 51:660-672, 1948
41. Shen S, DeNardo GL, Sgouros G, et al: Practical determination of patient-specific marrow dose using radioactivity concentration in blood and body. J Nucl Med 40:2102-2106, 1999
42. Nadali G, Tavecchia L, Zanolin E, et al: Serum level of the soluble form of the CD30 molecule identifies patients with Hodgkin's disease at high risk of unfavorable outcome. Blood 91:3011-3016, 1998
43. Order SE, Porter M, Hellman S: Hodgkin's disease: Evidence for a tumor-associated antigen. N Engl J Med 285:471-474, 1971
44. Eshhar Z, Order SE, Katz DH: Ferritin, a Hodgkin's disease associated antigen. Proc Natl Acad Sci U S A 71:3956-3960, 1974
45. Yuen AR, Higgins JP, Baker R, et al: Distribution of monoclonal antiferritin antibody in Kaposi's sarcoma, Hodgkin's disease, and hepatocellular carcinoma. Hum Pathol 34:381-384, 2003
46. Falini B, Flenghi L, Fedeli L, et al: In vivo targeting of Hodgkin and Reed-Sternberg cells of Hodgkin's disease with monoclonal antibody Ber-H2 (CD30): Immunohistological evidence. Br J Haematol 82:38-45, 1992
47. Lai J, Quadri SM, Borchardt PE, et al: Pharmacokinetics of radiolabeled polyclonal antiferritin in patients with Hodgkin's disease. Clin Cancer Res 5:3315s-3323s, 1999
48. Witzig TE, White CA, Gordon LI, et al: Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-Hodgkin's lymphoma. J Clin Oncol 21:1263-1270, 2003
49. Kaminski MS, Zasadny KR, Francis IR, et al: Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma. J Clin Oncol 14:1974-1981, 1996
50. Cheson BD: Radioimmunotherapy of non-Hodgkin lymphomas. Blood 101:391-398, 2003
51. Press OW, Eary JF, Gooley T, et al: A phase I/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas. Blood 96:2934-2942, 2000